CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

por Ilyas, Rimal, McCullough, Kristen, Badar, Talha, Patnaik, Mrinal M., Alkhateeb, Hassan, Mangaonkar, Abhishek, Pardanani, Animesh, Tefferi, Ayalew, Gangat, Naseema
Publicado 2023

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

por Gangat, Naseema, Ilyas, Rimal, Johnson, Isla M., McCullough, Kristen, Al-Kali, Aref, Alkhateeb, Hassan B., Begna, Kebede H., Mangaonkar, Abhishek, Litzow, Mark R, Hogan, William, Shah, Mithun, Patnaik, Mrinal M., Pardanani, Animesh, Tefferi, Ayalew
Publicado 2023

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm

por Gangat, Naseema, Ilyas, Rimal, McCullough, Kristen, Begna, Kebede H., Al-Kali, Aref, Patnaik, Mrinal M., Litzow, Mark R., Hogan, William J., Mangaonkar, Abhishek, Alkhateeb, Hassan, Shah, Mithun V., Elliott, Michelle A., Foran, James M., Badar, Talha, Palmer, Jeanne M., Hanson, Curtis A., Pardanani, Animesh, Tefferi, Ayalew
Publicado 2022

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

por Abdallah, Mostafa, McCullough, Kristen, Ilyas, Rimal, Begna, Kebede H., Al-Kali, Aref, Litzow, Mark R., Hogan, William J., Mangaonkar, Abhishek, Alkhateeb, Hassan, Shah, Mithun V., Elliott, Michelle A., Foran, James M., Badar, Talha, Palmer, Jeanne M., Yi, Cecilia Arana, Sproat, Lisa, Pardanani, Animesh, Patnaik, Mrinal M., Olteanu, Horatiu, Ketterling, Rhett P., Tefferi, Ayalew, Gangat, Naseema
Publicado 2023